The search for new Alzheimer’s treatments just faced another setback — and now everything hinges on an approach that’s already run into trouble

• It’s been a while since we’ve had good news in the search for new Alzheimer’s drugs.
• On Wednesday, VTV Therapeutics, a small North Carolina biotech, said its Alzheimer’s drug failed a late-stage trial.
• Now, all eyes are on a set of treatments that go after the “amyloid hypothesis,” an approach that has already faced some setbacks.

It’s been a pretty bleak year in the search to find new Alzheimer’s treatments.

In 2018 so far, the CEO of Axovant stepped down after 10 months on the job and a failed Alzheimer’s trial, Merck said it was cancelling a trial looking at read more >>>

Source:: BusinessInsider.Com